The expression of GALT is controlled by the actions of the FOXO3 gene. The absence of this enzyme results in classic galactosemia in humans and can be fatal in the newborn period if lactose is not removed from the diet. The pathophysiology of galactosemia has not been clearly defined.
GALT catalyzes the second reaction of the Leloir pathway of galactose metabolism through ping pong bi-bi kinetics with a double displacement mechanism. This means that the net reaction consists of two reactants and two products (see reaction above), and it proceeds by the following mechanism: the enzyme reacts with one substrate to generate one product and a modified enzyme, which goes on to react with the second substrate to make the second product while regenerating the original enzyme. In the case of GALT, the His166 residue acts as a potent nucleophile to facilitate transfer of a nucleotide between UDP-hexoses and hexose-1-phosphates.
The three-dimensional structure at 1.8 angstrom resolution (x-ray crystallography) of GALT was discovered by Wedekind, Frey, and Rayment, and their structural analysis has found key amino acids essential for GALT function.
The important amino acids that Wedekind et al. found in their structural analysis of GALT, such as Leu4, Phe75, Asn77, Asp78, Phe79, and Val108, are consistent with residues that have been implicated both in point mutation experiments as well as in clinical screening to play a role in human galactosemia.
Deficiency of GALT causes classic galactosemia. Galactosemia is a childhood disease of hereditary nature. The autosomal recessive trait affects approximately 1 in every 40,000-60,000 live-born infants. Classical galactosemia (G/G) is caused by a deficiency in GALT activity, whereas the more common clinical affliction, Duarte/Classica (D/G) arises from attenuation of GALT activity. Symptoms include ovarian failure, developmental coordination disorder (difficulty speaking correctly and consistently), and neurologic deficits. A single mutation in any of several amino acids can lead to attenuation or deficiency in GALT activity. For example, a single mutation from A to G in exon 6 of the GALT gene changes Glu188 to an arginine, and a mutation from A to G in exon 10 converts Asn314 to an aspartic acid. These two mutations also add new restriction enzyme cut sites, which enable detection by and large-scale population screening with PCR (polymerase chain reaction). Screening has mostly eliminated neonatal death by G/G galactosemia, but the disease, due to GALT’s role in the biochemical metabolism of ingested galactose (which is toxic when accumulated) to the energetically useful glucose, can certainly be fatal. However, those afflicted with galactosemia can live relatively normal lives by avoiding milk products and anything else containing galactose (since it cannot be metabolized), although there is the potential for problems in neurological development, or other complications, even in those who avoid galactose.
^ abcdWedekind JE, Frey PA, Rayment I (September 1995). "Three-dimensional structure of galactose-1-phosphate uridylyltransferase from Escherichia coli at 1.8 A resolution". Biochemistry34 (35): 11049–61. doi:10.1021/bi00035a010. PMID7669762.
Reichardt JK, Belmont JW, Levy HL, Woo SL (1992). "Characterization of two missense mutations in human galactose-1-phosphate uridyltransferase: different molecular mechanisms for galactosemia". Genomics12 (3): 596–600. doi:10.1016/0888-7543(92)90453-Y. PMID1373122.
Reichardt JK, Levy HL, Woo SL (1992). "Molecular characterization of two galactosemia mutations and one polymorphism: implications for structure-function analysis of human galactose-1-phosphate uridyltransferase". Biochemistry31 (24): 5430–3. doi:10.1021/bi00139a002. PMID1610789.
Shih LY, Suslak L, Rosin I et al. (1985). "Gene dosage studies supporting localization of the structural gene for galactose-1-phosphate uridyl transferase (GALT) to band p13 of chromosome 9". Am. J. Med. Genet.19 (3): 539–43. doi:10.1002/ajmg.1320190316. PMID6095663.CS1 maint: Explicit use of et al. (link)
Ashino J, Okano Y, Suyama I et al. (1995). "Molecular characterization of galactosemia (type 1) mutations in Japanese". Hum. Mutat.6 (1): 36–43. doi:10.1002/humu.1380060108. PMID7550229.CS1 maint: Explicit use of et al. (link)
Elsas LJ, Langley S, Paulk EM et al. (1995). "A molecular approach to galactosemia". Eur. J. Pediatr.154 (7 Suppl 2): S21–7. doi:10.1007/BF02143798. PMID7671959.CS1 maint: Explicit use of et al. (link)
Davit-Spraul A, Pourci ML, Ng KH et al. (1994). "Regulatory effects of galactose on galactose-1-phosphate uridyltransferase activity on human hepatoblastoma HepG2 cells". FEBS Lett.354 (2): 232–6. doi:10.1016/0014-5793(94)01133-8. PMID7957929.CS1 maint: Explicit use of et al. (link)
Lin HC, Kirby LT, Ng WG, Reichardt JK (1994). "On the molecular nature of the Duarte variant of galactose-1-phosphate uridyl transferase (GALT)". Hum. Genet.93 (2): 167–9. doi:10.1007/BF00210604. PMID8112740.